Roche is disappointed that the National Institute for Health and Clinical Excellence (NICE) has published a negative final recommendation (FAD) for the use of Avastin (bevacizumab) in combination with paclitaxel and carboplatin for women with newly-diagnosed advanced ovarian cancer*...
News From The Journal Of Clinical Investigation: March 25, 2013
3/26/2013
A new therapeutic target in iron overload disorders Iron is required for multiple cellular functions, including the synthesis of hemoglobin, but a buildup of excess cellular iron can be toxic. Hepcidin is a circulating molecule produced by the liver that triggers the degradation of iron transporters in the intestine and certain immune cells...
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-small cell lung cancer (NSCLC), surgical resection remains the treatment of choice with adjuvant chemotherapy...
For Rapidly Increasing Form Of Esophageal Cancer, Molecular 'Signature' Found
3/26/2013
During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States...
Your cells are social butterflies. They constantly interact with their surroundings, taking in cues on when to divide and where to anchor themselves, among other critical tasks. This networking is driven in part by proteins called integrin, which reside in a cell's outer plasma membrane...
Research On Immune-Cell Therapy Could Strengthen Promising Melanoma Treatment
3/26/2013
A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer...
At the dawn of the third millennium medical researchers still know very little about gender-specific differences in illness, particularly when it comes to disease symptoms, influencing social and psychological factors, and the ramifications of these differences for treatment and prevention. Medical research conducted over the past 40 years has focused almost exclusively on male patients...
Young Adult Cancer Deaths Cut In Half In The U.K.
3/25/2013
The number of deaths among teenagers and young adults due to cancer in the UK has been cut in half since the 1970s, according to new data from Cancer Research UK. The number of deaths among children and young adults dropped from close to 580 annually in 1975-1977 to 300 in 2008-2010. The largest reduction was in young patients with leukemia...
New Nanoparticle Chemo Is Gentler On Fertility
3/25/2013
Using nanoparticles as "Trojan horses", scientists have designed and lab-tested a way to deliver an arsenic-based chemo drug that ferociously attacks cancer, but is gentler on the ovaries. They hope the new method will help to protect the fertility of women undergoing cancer treatment...
Researchers Study Use Of Dasatinib For Patients With High-Risk Myelodysplastic Syndromes
3/25/2013
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides...